MedTrace Logo

Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

NCT03128411 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2022-05-19

Study results available
· View outcomes & findings →

Summary

Phase 2, single-arm, open-label trial. Patients will receive bosutinib for the duration of the study.

Conditions

  • Leukemia, Chronic Myelogenous

Interventions

DRUG

Bosutinib

All patients will receive bosutinib at a starting dose of 400 mg QD.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-15
Primary Completion
2019-03-12
Completion
2021-03-04

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03128411 on ClinicalTrials.gov